The study included 215 women with LGSOC with: 1) pathologically confirmed LGSOC, 2) availability of NGS data, and 3) adequate clinical data. Clinical subgroups were compared for progression-free survival (PFS) and OS. Multivariable Cox regression analysis was performed.
Median age at diagnosis was 46.6 years. The majority had a stage III ovarian primary. One or more mutations were identified in 140 (65.1%) cases; 75 (34.9%) had none. The most common mutations were KRAS (n = 71; 33.0%), NRAS (n = 24; 11.2%), and BRAF (n = 18; 8.4%). Patients with MAPK-mutated tumors (n = 113) (52.6%) had a significantly longer OS compared to those with tumors lacking MAPK pathway mutations (n = 102) (47.4%) [median OS, 147.8 months (95% CI,119.0-176.6) versus 89.5 months (95% CI, 61.4-117.7) (p = 0.01)], respectively. Median OS for patients with MAPK-mutated tumors was also significantly better than for patients whose tumors had no mutations (n = 75) [median OS, 147.8 months (95% CI, 119.0-176.6) versus 78.0 months (95% CI, 57.6-98.3)], respectively (p = 0.001). Median OS for patients with non-MAPK-mutated tumors (n = 27) was 125.1 months (95% CI, 83.9-166.3). In multivariable analysis, having a MAPK mutation was associated with improved OS.
Patients with MAPK-mutated tumors have a significantly improved OS compared to those without MAPK-mutated tumors.
该研究包括215名LGSOC女性,其中:1)经病理证实的LGSOC,2)NGS数据的可用性,3)充分的临床资料。比较临床亚组的无进展生存期(PFS)和OS。进行多变量Cox回归分析。
诊断时的中位年龄为46.6岁。大多数患有III期卵巢原发性。在140例(65.1%)中发现了一个或多个突变;75例(34.9%)没有突变。最常见的突变是KRAS(n=71;33.0%),NRAS(n=24;11.2%),和BRAF(n=18;8.4%)。与缺乏MAPK通路突变的肿瘤患者(n=102)(47.4%)相比,MAPK突变的肿瘤患者(n=113)(52.6%)的OS明显更长[中位OS,147.8个月(95%CI,119.0-176.6)与89.5个月(95%CI,61.4-117.7)(p=0.01)],分别。MAPK突变肿瘤患者的中位OS也明显优于无突变肿瘤患者(n=75)[中位OS,147.8个月(95%CI,119.0-176.6)与78.0个月(95%CI,57.6-98.3)],分别(p=0.001)。非MAPK突变肿瘤患者(n=27)的中位OS为125.1个月(95%CI,83.9-166.3)。在多变量分析中,MAPK突变与OS改善相关。
与没有MAPK突变肿瘤的患者相比,MAPK突变肿瘤的患者的OS明显改善。